IO Biotech begins phase III trial with partner MSD

IO Biotech joins forces with partner MSD in the development of a new therapy for the treatment of skin cancer in combination with IO Biotech's lead candidate Keytruda. A big phase III trial now commences, and if successful, IO Biotech maintains commercial rights.


A possible breakthrough in the treatment of metastatic melanoma patients could be on the way. Around 290,000 people are diagnosed with the skin cancer every year.

The Danish cancer company IO Biotech has just entered into a partnership with the US pharmaceutical giant MSD. Together, they will develop a potential treatment against the serious cancer.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs